Results 81 to 90 of about 1,442,074 (300)

Bilirubin neurotoxicity is associated with proteasome inhibition [PDF]

Cell Death & Disease, 2017
AbstractThe molecular mechanism underlying bilirubin neurotoxicity remains obscure. Ubiquitin–proteasome system-mediated proteolysis is pivotal to virtually all cellular processes and cell survival. Here we report for the first time that bilirubin at a clinically relevant elevated level impairs proteasomal function via inhibiting both the 19S ...
Hongbiao Huang, Mingxing Guo, Ningning Liu, Chong Zhao, Haoyu Chen, Xiaoli Wang, Siyan Liao, Ping Zhou, Yuning Liao, Xin Chen, Xiaoying Lan, Jinghong Chen, Dacai Xu, Xiaofen Li, Xianping Shi, Li Yu, Yuqiang Nie, Xuejun Wang, Chang-E Zhang, Jinbao Liu   +19 more
openaire   +2 more sources

Proteasome inhibition.

, 2014
Cells transfected with A455E cDNA were treated either with MG132, a more general inhibitor (n = 6) (A, B), or the more specific inhibitor of proteasomes, PS341 (n = 2) (C).
Daniele Rapino (506785), Liudmila Cebotaru (294192), William B. Guggino (243320), Valeriu Cebotaru (506786)   +3 more
core   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

Molecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis, Tereza Buchtová, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen, Zuzana Machacova, Zdenek Skrott, Martin Mistrik, Ekaterina Dulina, Miguel Andujar‐Sanchez, Estrid Høgdall, Tine Henrichsen Schnack, Claus Høgdall, Berit Jul Mosgaard, Marie Boennelycke, Jacob Brink Laursen, Allan Jensen, Susanne K. Kjær, Tuula Kallunki, Robert Strauss, Jiri Bartek   +20 more
wiley   +1 more source

Proteasome Inhibition Measurements: Clinical Application [PDF]

Clinical Chemistry, 2000
AbstractBackground: PS-341, a selective inhibitor of the proteasome, currently is under evaluation as an anticancer agent in multiple phase I clinical trials. In animal-model studies, PS-341 was rapidly removed from the vascular compartment and distributed widely, quickly approaching the limits of detection.
E S, Lightcap, T A, McCormack, C S, Pien, V, Chau, J, Adams, P J, Elliott   +5 more
openaire   +2 more sources

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source

Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model

Translational Oncology, 2014
Inhibition of the proteasome offers many therapeutic possibilities in inflammation as well as in neoplastic diseases. However, clinical use of proteasome inhibitors is limited by the development of resistance or severe side effects.
Izabela Mlynarczuk-Bialy, Thorsten R. Doeppner, Jakub Golab, Dominika Nowis, Grzegorz M. Wilczynski, Kamil Parobczak, Moritz E. Wigand, Malgorzata Hajdamowicz, Łukasz P. Biały, Olga Aniolek, Petra Henklein, Mathias Bähr, Boris Schmidt, Ulrike Kuckelkorn, Peter-M. Kloetzel   +14 more
doaj   +1 more source

Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
The highly conserved ubiquitin-proteasome system is the principal machinery for extralysosomal protein degradation in eukaryotic cells. The 26S proteasome, a large multicatalytic multisubunit protease that processes cell proteins by limited and controlled proteolysis, constitutes the central proteolytic component of the ubiquitin-proteasome system.
Naujokat, Cord, Fuchs, Dominik, Berges, Carsten   +2 more
openaire   +2 more sources

Accurate and noninvasive prostate cancer detection using plasma‐derived extracellular vesicle RNA

FEBS Open Bio, EarlyView.
Plasma extracellular vesicles were captured with WGA‐conjugated magnetic beads and profiled for RNA biomarkers. A three‐RNA panel (NM_024955, NR_047469, and NR_002564) distinguished prostate cancer from healthy controls and benign prostatic hyperplasia, supporting a simple, noninvasive approach to improve prostate cancer detection.
Hanping Wei, Haoran Wu, Wei Feng
wiley   +1 more source

Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding. [PDF]

PLoS ONE, 2013
The proteasome is a proteolytic machinery that executes the degradation of polyubiquitinated proteins to maintain cellular homeostasis. Proteasome inhibition is a unique and effective way to kill cancer cells because they are sensitive to proteotoxic ...
Jiro Kikuchi, Naoya Shibayama, Satoshi Yamada, Taeko Wada, Masaharu Nobuyoshi, Tohru Izumi, Miyuki Akutsu, Yasuhiko Kano, Kanako Sugiyama, Mio Ohki, Sam-Yong Park, Yusuke Furukawa   +11 more
doaj   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source